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A B S T R A C T
The initiation and maintenance phases of cholinergic status epilepticus (SE) are associated with maladaptive trafficking of synaptic GABAA and glutamate receptors.
The resulting pharmacoresistance reflects a decrease in synaptic GABAA receptors and increase in NMDA and AMPA receptors, which tilt the balance between
inhibition and excitation in favor of the latter. If these changes are important to the pathophysiology of SE, both should be treated, and blocking their consequences
should have therapeutic potential.
We used a model of benzodiazepine-refractory SE (RSE) (Tetz et al., 2006) and a model of soman-induced SE to test this hypothesis. Treatment of RSE with
combinations of the GABAAR agonists midazolam or diazepam and the NMDAR antagonists MK-801 or ketamine terminated RSE unresponsive to high-dose
monotherapy with benzodiazepines, ketamine or other antiepileptic drugs (AEDs). It also reduced RSE-associated neuronal injury, spatial memory deficits and the
occurrence of spontaneous recurrent seizures (SRS), tested several weeks after SE. Treatment of sc soman-induced SE similarly showed much greater reduction of EEG
power by a combination of midazolam with ketamine, compared to midazolam monotherapy.
When treating late (40min after seizure onset), there may not be enough synaptic GABAAR left to be able to restore inhibition with maximal GABAAR stimulation, and
further benefit is derived from the addition of an AED which increases inhibition or reduces excitation by a non-GABAergic mechanism. The midazolam-ketamine-valproate
combination is effective in terminating RSE. 3-D isobolograms demonstrate positive cooperativity between midazolam, ketamine and valproate, without any interaction
between the toxicity of these drugs, so that the therapeutic index is increased by combination therapy between GABAAR agonist, NMDAR antagonist and selective AEDs.
We compared this drug combination based on the receptor trafficking hypothesis to treatments based on clinical practice. The midazolam-ketamine-valproate
combination is far more effective in stopping RSE than the midazolam-fosphenytoin-valproate combination inspired from clinical guidelines. Furthermore, sequential
administration of midazolam, ketamine and valproate is far less effective than simultaneous treatment with the same drugs at the same dose. These data suggest that
we should re-evaluate our traditional treatment of RSE, and that treatment should be based on pathophysiology. The search for a better drug has to deal with the fact
that most monotherapy leaves half the problem untreated. The search for a better benzodiazepine should acknowledge the main cause of pharmacoresistance, which
is loss of synaptic GABAAR. Future clinical trials should consider treating both the failure of inhibition and the runaway excitation which characterize RSE, and
should include an early polytherapy arm.
1. Introduction
Because of the ease with which they are synthesized, concealed and
of their potential for mass casualties, nerve agents are among the most
serious terrorist threats to day. Military stockpiles reach gigantic levels
in many countries. The potential terrorist threat is even greater, be-
cause agents such as sarin can easily be synthesized, transported, con-
cealed and of the potential availability of some military stockpiles to
terrorists. Seizures are the most treatment-refractory complication of
nerve agent intoxication, and were a prominent feature in the Tokyo
subway attacks (Nakajima et al., 1998) and in the recent use of nerve
agents in Syria. They turn into uncontrolled status epilepticus (SE),
refractory to treatment with antiepileptic drugs and cause severe brain
damage (Shih et al., 1999, McDonough Jr. and Shih, 1993) and chronic
epilepsy (de Araujo Furtado et al., 2010). Finding a treatment for those
seizures is clearly an important national goal. In addition, the insights
and practical applications derived from this study are likely to find
applications in the treatment of organophosphate insecticide poisoning,
which occurs through agricultural or voluntary (attempted suicide)
exposure throughout the world, and in the treatment of status epi-
lepticus (SE), a condition affecting 102–152,000 cases/year in the USA,
with an estimated 22–42,000 deaths yearly (DeLorenzo et al., 1996).
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While some aspects of nerve agent-induced SE are unique, its classical
features have much in common with other forms of SE (Chen and
Wasterlain, 2006). It becomes self-sustaining, independent of its ori-
ginal cholinergic trigger, pharmacoresistant to benzodiazepines (Shih
et al., 1999), and remains relatively responsive to NMDA blockers
(Dorandeu et al., 2019), but these features are shared by SE induced by
perforant path stimulation (Mazarati et al., 1998a, 1998b, Mazarati and
Wasterlain, 1999), amygdala stimulation (Nissinen et al., 2000), or li-
thium and pilocarpine (Morrisett et al., 1987; Suchomelova et al.,
2006). It is probably shared by human SE, where the time of treatment
is a better determinant of therapeutic response than the drug used
(Treiman et al., 1998). The therapeutic lessons of this study are likely to
apply to these other forms of SE as well.
While we have made considerable progress in treating nerve agent
intoxication, their tendency to produce severe seizures and SE remains
a therapeutic challenge. These seizures quickly become self-sustaining,
independent of the cholinergic network, and refractory to antic-
onvulsants (Shih et al., 1999; Kapur and Macdonald, 1997; Mazarati
et al., 1998b). They display reduced GABAergic inhibition (Kapur et al.,
1989, Rice and DeLorenzo, 1999, Naylor and Wasterlain, 2005a,
2005b) and enhanced glutamatergic excitation (Kapur and Lothman,
1990; Wasterlain et al., 2000; Naylor et al., 2013). Our studies and
others, using a cholinergic SE model induced by lithium-pilocarpine,
suggest that seizures cause internalization (and inactivation) of sy-
naptic GABAA receptors (GABAAR) (Naylor et al., 2005; Goodkin et al.,
2008), and promote movement of NMDA receptor (NMDAR) subunits to
synapses where they form additional functional receptors (Naylor et al.,
2013) and NMDA-dependent movement of AMPA receptors (AMPAR)
to synapses (Rajasekaran et al., 2012). It should be noted that the
changes in AMPAR described in SE are NMDAR-activation-dependent,
so that blocking NMDAR may block the changes induced by both
NMDAR and AMPAR.
The loss of synaptic GABAA receptors and the increase in synaptic
NMDAR and AMPAR are proconvulsant and maintain seizure activity.
This might explain why muscarinic antagonists, which are very effec-
tive in blocking seizure development when given early during nerve
agent intoxication, cannot stop the seizures once they have become
established. Blocking muscarinic receptors does not correct the reduced
number of synaptic GABAAR or the increased number of synaptic
NMDAR and AMPAR, it amounts to closing the barn door after the
horses have escaped. This suggests that targeting a single mechanism
(e.g. GABAAR) is unlikely to be successful, and that polytherapy is
needed to 1/stimulate the remaining GABAAR; 2/reduce the activity of
NMDAR; 3/enhance inhibition by a non-GABA, non-NMDA mechanism,
since strategy number 1/, while useful, cannot fully restore inhibition if
the reduction of the number of synaptic GABAAR is severe. The choice
of the third drug is beyond the scope of this review. Valproate, a drug
with an unknown mechanism of action and no affinity for GABAAR, is
one of several antiepileptic drugs (AEDs) which we found to be effec-
tive.
Since we have not been successful at blocking seizure-induced re-
ceptor trafficking in vivo, we examined whether blocking its con-
sequences might achieve the same result. Indeed, treatment of choli-
nergic seizures with combinations of drugs which enhance GABAAR
mediated inhibition, and block NMDAR mediated excitation proved
very effective in the treatment of cholinergic SE. Using this approach,
we can stop severe cholinergic seizures using subanesthetic doses of
drugs while limiting toxicity. Nerve agents and organophosphate in-
secticides inhibits acetylcholinesterase (Ache), and have both mus-
carinic and nicotinic effects. Seizures are prevented by early adminis-
tration of atropine, scopolamine and muscarinic blockers, and
untouched by nicotinic antagonists (McDonough Jr. and Shih, 1993),
suggesting that the muscarinic component is responsible for the ma-
jority of ictogenic effects. This led to the development of models based
on the administration of lithium and pilocarpine (Tetz et al., 2006) to
mimic seizures induced by soman. We used that model in most of our
studies. The most effective drug combinations in this model were then
tested in a model of SE induced by subcutaneous injection of the nerve
agent soman (also named GD). The similarity of therapeutic results in
these two seizure types suggests that the high-dose lithium-pilocarpine
model of SE is highly predictive of nerve agent-induced SE.
2. Methods
The detailed methods have been published (Niquet et al., 2016a,b;
Niquet et al., 2017a,b; Schultz et al., 2014) and will be described
briefly.
2.1. Animals
Male Sprague-Dawley rat (200–300 g, mean 249 g; Charles River,
MA) were housed in a temperature- and humidity- controlled room with
12 h light-dark cycles and had free access to food and water. All ex-
periments were conducted with the approval and in accordance with
the regulations of the Institutional Animal care and Use Committee of
West Los Angeles VA Medical Center. For the soman studies, male
Sprague-Dawley rats (350–400 g; Charles River) were housed on 12 h
reverse light-dark cycle. The experimental protocol was approved by
the Animal Care and Use Committee at both the United States Army
Medical Research Institute of Chemical Defense and all procedures were
conducted in accordance with the principles stated in the Guide for the
Care and Use of Laboratory Animals, and the Animal Welfare Act of
1966 (P.L. 89-544), as amended.
2.2. Induction of SE, monotherapy and polytherapy
Rats were administered lithium chloride (5mEq/kg) subcutaneously
and, 16 h later, SE was induced with i.p. pilocarpine hydrochloride
(320mg/kg). Only rats displaying behavioral/EEG seizures were used.
All rats received scopolamine methyl bromide (1mg/kg; i.p.), a mus-
carinic antagonist that does not cross the blood-brain barrier, at the
same time as pilocarpine, to decrease peripheral cholinergic side-effects
such as bronchial secretions. Seizures occurred 7.6 ± 2.7min after
pilocarpine injection, so that time from pilocarpine injection to mono or
dual therapy was approximately 48min. All animals subsequently re-
ceived scopolamine (10mg/kg i.p.) to remove the original seizure
trigger without stopping SE, and sham injection (control SE group), one
drug (monotherapy) or a combination of drugs (polytherapy) i.p.
40min after EEG seizure onset. Drugs included midazolam, ketamine
and sodium valproate. The valproate group was used as an additional
“control” group because mortality rate in the SE control group was
high, and valproate monotherapy did not measurably alter seizure ac-
tivity. Note that monotherapy groups have double or triple dose of
drugs compared to polytherapy groups to compensate for the total
amount of drugs. For long-term behavioral studies, a sham group,
which did not receive drug treatment and was not exposed to SE, was
added.
Rats not capable of coordinated walking and movement 16 h after
SE were injected SC (10ml/kg) with 5% glucose twice per day until
capable of coordinated movement or until euthanasia at three days.
Water moistened food pellets and/or gelatin cubes were placed in the
cage in Petri dishes. Euthanasia criteria consisted of failure to achieve
coordinated movement three days after SE. Animals were also eu-
thanized if showing a weight loss of 5% sustained over two days after
the coordination criterion had been achieved.
2.3. Soman exposure
Rats were subcutaneously (s.c.) administered 1.2 LD50 GD (pina-
colyl methylphosphonofluoridate; 132 μg/kg; 0.5ml/kg) obtained from
Edgewood Chemical Biological Center (Aberdeen Proving Ground, MD,
USA) and 1min later administered an intramuscular (i.m.) injection
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with an admix of atropine sulfate (2mg/kg) and the oxime HI-6 di-
methanesulfonate salt (93.6 mg/kg). Forty minutes after seizure onset,
drugs (midazolam, ketamine or sham injection) were administered i.p.
as either a monotherapy or a polytherapy.
2.4. Implantation of electrodes
Under isoflurane anesthesia, the animals were implanted with
stainless steel skull screws to serve as recording electrodes. Two elec-
trodes were used for bipolar recording and were located 3mm anterior
to lambda and 4mm left and right of the medial suture. The third
electrode served as reference and was located 1mm anterior to bregma
and 1mm to the right of the mid-line defined by the medial suture. The
screw electrodes were connected to a tri-polar connector (Plastics One,
VA) and dental cement was used to cover the electrodes so that only the
connector was exposed. Animals were used one to two weeks after
electrode implantation. The BioPac Systems MP150 was used to record
digital EEG using a BioPac UM100A preamplifier. Sampling rate was
200 Hz.
For soman studies, rats were implanted with F40-EET telemetry
transmitters (Data Sciences International, Inc.) as described in Schultz
et al., 2014 and received continuous EEG recording.
2.5. Acute video-EEG monitoring
Recording was started before agent (pilocarpine or soman) exposure
and was continuous for 24 h. For pilocarpine EEG analysis, the EEGs
were processed offline to detect seizures and spikes using Stellate
Systems Harmony software (Natus) with default parameters: amplitude
threshold 2.7, minimum frequency 3 Hz, maximum coefficient of var-
iation 40% for seizure detection and a spike amplitude threshold of 6
for spike detection. For soman EEG analysis, epileptiform activity was
identified using Dataquest ART 4.1 (analysis software), Neuroscore
1.1.1 (Data Systems International, Arden Hills, MN), and a customized
MATLAB (release 2008a, Mathworks, Natick, MA) algorithm according
to de Araujo Furtado et al. (2009) and confirmed by visual screening.,
The outcome measures were the ratio of EEG power integral over a
defined period of time divided by the average baseline EEG power
before exposure; the number of seizures per 24 h, the cumulative sei-
zure time per 24 h (time spent seizing, subtracting post- and inter-ictal
time); the number of spikes per 24 h; and the time needed for EEG
amplitude to fall for the first time below 2 times the pre-pilocarpine
EEG amplitude and be free of semi-periodic spikes or sharp waves for at
least 1min, which in this experimental paradigm is close to the time of
termination of SE.
2.6. Tissue preparation for detection of acute neuronal injury
The animals were anesthetized with an overdose of pentobarbital
(100mg/kg i.p.) 48 h after induction of SE, and after transcardiac per-
fusion with 4% phosphate-buffered formaldehyde brains were kept in
situ at 4 °C overnight, postfixed in the same perfusate for 2–3 h. and
kept in PB 0.1M containing 30% sucrose for 48–72 h. Floating sections
(30 μM thickness) were obtained using a sliding microtome. Coronal
sections were stained with fluoro-Jade B. When needed, the number of
injured cells was counted by unbiased stereology using the optical
dissector method.
2.7. Recording of spontaneous recurrent seizures (SRS)
For chronic recordings, rats were implanted 4 weeks after pilo-
carpine-induced SE and monitored 2 weeks later for 2 weeks (24/7)
with a digital video-EEG system. Electrographic seizures were analyzed
off-line and seizures were confirmed by manual review of the tracing
morphology and of the digital videos. Outcome measure was the
average number of SRS per week.
2.8. Morris water maze paradigm
In pilocarpine exposed rats, spatial learning and memory were
evaluated one week after SRS recording with a modified Morris water
maze paradigm, by requiring the rats to swim in a pool 170 cm in
diameter, with the water kept at 260 °C, to find a 12-cm diameter cir-
cular platform submerged 2 cm beneath the surface of the water, which
was opacified by the addition of black non-toxic tempera paint. The
platform was in a constant position during training, as there were a
number of visual cues in the testing room. Experiments were monitored
with a Sony CCD-IRIS high-resolution camera mounted above the pool
and using indirect lighting from a 25W bulb. A video-tracking system
(Ethovision; Noldus, Inc. Wageningen, The Netherlands) was used for
data acquisition. The rats were brought to the experimental room at
least 30min prior to an experiment. Each rat was trained to find the
hidden platform kept in the same location for one session of eight trials
per day, for 5 consecutive days. The start sequence was randomly se-
lected and was different for each day. For training, the rat was released
in the water from one of the four starting positions, facing the wall of
the pool. It was given 60s to locate and climb onto the platform, where
it stayed for 30s. If a rat did not find the platform within 60s, it was
gently guided to it by experimenter. After the end of the last session, the
rat was dried with absorbent paper and kept in a warm cage. Ten days
later, retention test for long-term memory retention was performed.
Soman-exposed rats were evaluated one month after exposure for
spatial memory acquisition in the Morris water maze using a video-
tracking program (HVS Watermaze 2100, HVS Image, Cambridge, UK),
using a similar paradigm to that described above. For detailed methods,
see Schultz et al., 2014.
2.9. Toxicity studies
The following scale was used: 0 normal gait; 1 ataxic; 2 unable to
walk but able to crawl, righting reflex preserved; 3 righting reflex
partially impaired; 4 complete loss of righting reflex; 5 no response to
tail pinch; 6 loss of corneal reflex. The toxicity score was the sum of
measures taken every 15min for the first hour after injection.
2.10. Construction of 3-dimensional isobolograms for toxicity and efficacy
We defined the ED50 as the dose which reduced a particular mea-
sure of seizure severity by 50%, and the TD50 as the dose which in-
duced half-maximal toxicity. Dose-response curves were fit by the
method of Chou (2006).10 The variances of the TD50s were calculated
by the method of Tallarida (p 29, equation 2.9).11 The theoretical
dosage sum was calculated from Tallarida (p 59, equation 4.1, and its
variance from equation 4.2, p 60). For each isobologram, a plane was fit
through the ED50s or TD50s using SciDavis (http://scidavis,
sourceforge.net). The observed toxicity or efficacy of the triple drug
combination was then placed in the same 3 dimensional plot with the
plane connecting TD50s or ED50s for individual drugs. Drug synergism
(positive cooperativity) is indicated if the observed toxicity or efficacy
of the combination lies below the additivity plane in the isobolograms.
When the effects are simply additive, the values fall in the additivity
plane. Negative cooperativity would result in values above that plane.
Significance was determined by a modified t-test (Tallarida, Section 2.3,
p 60–62).11
2.11. Statistical analyses
EEG and cell injury data often showed a non-Gaussian distribution
and were analyzed with nonparametric statistical methods: Kruskal-
Wallis test followed by Dunn's multiple comparison test (GraphPad
version 6). MWM data was analyzed by 2-way ANOVA (GraphPad
version 6). Kaplan-Meier analysis was used for comparison of soman
induced SRS. Statistical significance was defined as p < 0.05. In all
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graphs, data are presented as median values with the interquartile
range, which is the difference between the 75th and 25th percentile.
When data were normally distributed, we used mean ± SEM.
3. Results and discussion
3.1. Biological basis for treatment of cholinergic SE with drug combinations
The transition from single seizures to SE (the initiation phase of SE)
and the maintenance of self-sustaining seizures (the maintenance phase
of SE) have been extensively studied in the lithium-pilocarpine model of
SE, in nerve agent-induced SE, and in non-cholinergic models, which
we will not review. In cholinergic animal models, SE is associated with
three key changes: 1/ internalization of synaptic GABAAR (Fig. 1A)
coupled with a decrease in GABAA mIPSCs (Fig. 1C) indicating a re-
duction of the number of post-synaptic GABAAR per synapse (Naylor
et al., 2005). This may represent a seizure-induced acceleration of the
normal process of receptor trafficking, in which synaptic GABAAR are
internalized into endosomes and transiently inactivated, and can later
be recycled to the Golgi apparatus and to the synaptic membrane
(Terunuma et al., 2008; Nakamura et al., 2015). Interestingly, extra-
synaptic GABAAR, which have high affinity for GABA and do not de-
sensitize easily (Ferando and Mody, 2012), are not internalized during
SE, making them potential therapeutic targets (Naylor et al., 2005). 2/
Increased synaptic localization of NMDAR (Fig. 1B), coupled with an
increase in NMDA mEPSCs (Fig. 1C) reflecting an increased number of
NMDAR per synapse, presumably representing assembly and movement
to the membrane of spare NMDAR subunits. 3/ Increased AMPA/Kai-
nate synaptic currents after SE in dentate granule cells (Naylor and
Wasterlain, 2005a, 2005b), and NMDAR-dependent increased surface
localization of GluA1, but decreases in GluA2 AMPAR subunits in CA1,
but not in DG (Rajasekaran et al., 2012, Joshi and Kapur, 2018), pre-
sumably reflecting assembly and movement to the membrane of spare
GluA1 subunits. All three of those changes are maladaptive. The re-
duction of post-synaptic GABAAR can lead to failure of inhibition, and
the increase of post-synaptic NMDAR and AMPAR can lead to runaway
Fig. 1. A) In a control dentate gyrus, the γ2 subunits
of GABAA R (red pseudocolor, left) and the synaptic
marker synaptophysin (green pseudocolor) coloca-
lize (yellow colour) on synapses on the somatic sur-
face and proximal dendrites of dentate granule cells,
but after 1 h of SE induced by lithium 3mEq/kg and
pilocarpine 100mg/kg, many are internalized in the
cytoplasm, and there are fewer co-localizations. B)
The opposite happens to NR1 subunits of the
NMDAR (red pseudocolor, right) which are abundant
in the cytoplasm of controls, but during SE move to
the neuronal surface where they colocalize (yellow
dots) with synaptophysin (green). C) On the left, we
recorded GABAA miniature inhibitory synaptic cur-
rents (mIPSCs), which under the conditions of the
experiment reflect the response of post-synaptic
GABAAR to a quantum of GABA released from a
single synaptic vesicle. mIPSCs on the soma of den-
tate granule cells are of lower amplitude in the slice
prepared from a rat in lithium-pilocarpine SE for 1 h
(red line) than in the control slice (black line). Based
on a seven-state model of the GABAAR (Naylor et al.,
2005), this indicates a reduction in the number of
GABAAR per synapse (C: 36 ± 11 GABAAR/synapse,
SE: 18 ± 4 GABAAR/synapse, p < 0.001). (For in-
terpretation of the references to colour in this figure
legend, the reader is referred to the web version of
this article.)
In the center, we recorded miniature excitatory
NMDA post-synaptic currents (NMDA mEPSCs) from
dentate granule cells under similar conditions, re-
flecting the response of post-synaptic NMDA re-
ceptors to a quantum of glutamate released from a
single vesicle. Here, the amplitude of the post-
synaptic response to a quantum of glutamate is
greater in the slice from a rat in SE (red line) than in
a control (black line). Based on the model of the
NMDAR used by Naylor et al. (2013), this indicates
an increase in number of NMDA receptors per sy-
napse in SE (C: 8 ± 1 NMDAR/synapse, SE: 11 ± 2
NMDAR/synapse, p < 0.001). On the right, we re-
corded miniature excitatory AMPA/Kainate minia-
ture post-synaptic currents (Non-NMDA mEPSCs)
from dentate granule cells under similar conditions, reflecting the response of post-synaptic AMPA/Kainate receptors to a quantum of glutamate released from a
single vesicle. The amplitude of the postsynaptic response is slightly but significantly greater in the slice from a rat in SE (red line) than in a control (black line),
indicating an increased response of post-synaptic AMPAR and/or Kainate receptors to a quantum of glutamate in SE, due to increased number or increased activity of
these receptors. Here, we did not have immunocytochemistry to differentiate between these two options. AMPA/Kainate-mEPSCs amplitude increased from
−10.8 ± 1.2 pA in controls to −12.8 ± 1.6 pA after SE (p < 0.001). There was no change in the single channel conductance (13 ± 2 pS and 12 ± 2 pS for C and
SE, respectively; n.s.), but an increase in the number of AMPA/Kainate receptors per synapse from 32 ± 6 to 39 ± 4 (p < 0.001). AMPA/Kainate-mEPSCs also
have an increased tau decay from 5.01 ± 0.63 to 5.66 ± 0.76 (p < 0.05) with SE, but no significant change in event frequency.
Modified from Naylor et al., 2005, 2013.
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excitation.
The receptor trafficking hypothesis states that seizure-induced re-
ceptor trafficking (loss of synaptic GABAAR and increase in synaptic
ionotropic glutamate receptors) is a key factor in the development of
SE-associated pharmacoresistance. This does not rule out a role for the
many other physiological changes which are known to occur during SE,
including changes in transmitter release. However, it suggests that
blocking receptor trafficking or its consequences has the potential to
overcome that pharmacoresistance and to make seizures responsive to
drug treatment even when that treatment is delayed.
At present, we cannot prevent SE-associated receptor trafficking,
but we can block its consequences. We can stimulate remaining sy-
naptic GABAAR with benzodiazepines or other GABAergic drugs. If
treatment is late and too few GABAAR are left in synapses to fully re-
store inhibition by that mechanism, we can add a drug which increases
inhibition by a non-GABAergic mechanism (or reduces excitation). And
we can use NMDAR and AMPAR blockers to reduce excitation.
Combining GABAAR agonist and NMDAR antagonist drugs in the initial
treatment of SE is not recommended by current therapeutic guidelines
(Glauser et al., 2016), but is effective in the high-dose lithium/pilo-
carpine model (Tetz et al., 2006) and in a soman model of cholinergic
SE, as shown below.
3.2. Synergistic effects of the GABAAR agonist – NMDAR antagonist
combination in treating benzodiazepine-refractory cholinergic SE (RSE)
Trafficking of GABAA and ionotropic glutamate receptors is one of
many changes which occur at the transition from single seizures to SE.
If they are indeed the key to the initiation and maintenance of SE,
treatment which blocks these changes should stop SE. Indeed, previous
studies have suggested a synergistic seizure-stopping interaction be-
tween diazepam and the NMDAR channel blocker ketamine (Martin
and Kapur, 2008). We treated cholinergic SE with a combination of a
benzodiazepine (diazepam or midazolam) and an NMDAR antagonist
(dizocilpine or ketamine).
3.2.1. High-dose lithium-pilocarpine model
We used MK-801 (dizocilpine), a potent and specific, non-subunit
selective NMDA antagonist, to test the principle that a combination of a
benzodiazepine with an NMDA antagonist would be superior to
monotherapy with ei mortality (1/11 death/24 h vs 12/21 controls) but
not duration of SE, cumulative seizure time, time to the first seizure-free
minute or Hjorth function (Hjorth, 1991). Moderate to high doses of the
GABAA-enhancing benzodiazepine diazepam (5–20mg/kg) reduced
mortality (0/18) but did not affect duration of SE, seizure number, time
to the first seizure-free minute, cumulative seizure time or Hjorth
function. However, the combination of diazepam with dizocilpine was
very effective in stopping SE, eliminating mortality (0/8) and reducing
the duration of SE over 100-fold compared to the untreated and dia-
zepam groups (Fig. 2A). Compared to the same groups, it also reduced
the latency to the first seizure-free minute of EEG 74-165-fold, and
Hjorth function at 1 h (a measure of the severity of the initial seizures
which is influenced by EEG power) 10–14-fold (both p < 0.05). These
results support the hypothesis that cholinergic SE utilizes circuits in-
volving GABAA and NMDA receptors, and that cholinergic SE-asso-
ciated changes in number of available synaptic NMDAR play an im-
portant role in the maintenance of seizures. See (Fig. 2B).
Since dizocilpine is not approved for human use, we examined
whether similar results could be obtained with the low-affinity NMDA
channel blocker ketamine, which has been in clinical use for many
years, is available in injectable form and is well-absorbed in-
tramuscularly (important for treating mass casualties), has an excellent
safety record for anesthesia, and has been used successfully for the
treatment of refractory SE (Sheth and Gidal, 1998; Mewasingh et al.,
2003; Bleck, 2006; Holtkamp et al., 2005). The combination of low-
dose ketamine (10mg/kg) with moderate dose diazepam (5mg/kg)
reduced the duration of SE six-fold, and the number of seizures 9-fold
compared to the control, diazepam 20mg/kg and diazepam 5mg/kg
groups (p < 0.001), and also reduced the delay to the first seizure-free
minute of EEG, and Hjorth function, a measure highly correlated to EEG
power, over the first hour post-treatment. Hjorth function was also
reduced over the first 6 hours post-treatmernt, indicating that seizures
did not recur. It also decreased EEG power integral over the first hour
following treatment, while EEG power immediately before treatment
was the same in all groups (Niquet et al., 2016a,b). Some of ketamine's
actions are independent of the NMDAR (Zanos et al., 2016, 2018), but
here the effect on SE was probably NMDAR-mediated, since dizocilpine,
a fairly selective blocker of the NMDAR ion channel, had similar ac-
tions. It should be noted that not all drug combinations are efficacious.
In additional experiments, double-dose midazolam monotherapy and
double-dose ketamine monotherapy, and dual therapy combining
midazolam with valproate or ketamine with valproate decreased EEG
power slightly compared to untreated SE, but none of them stopped SE
(Niquet et al., 2016a,b). By contrast, the combination midazolam-ke-
tamine decreased EEG power integral below the pre-pilocarpine base-
line, showing that seizures stopped (Niquet et al., 2016a,b). These re-
sults confirm previous observations and suggest that a GABAAR agonist-
NMDAR antagonist combination has synergistic actions in the treat-
ment of cholinergic SE.
We attempted to determine NMDAR subunit specificity by using
NMDAR blockers which are selective for its GluN2A or GluN2B sub-
units. However, combinations of midazolam with the relatively selec-
tive GluN2A blocker TCN201 were poorly effective in stopping RSE.
Combinations of midazolam with the GluN2B blockers ifenprodil, fel-
bamate or Ro25–6981 were also less effective than combinations which
included dizocilpine or ketamine in blocking RSE 40min after seizure
onset. More detailed studies are needed to resolve the NMDAR subtype
involved in the therapeutic actions described in Fig. 2A.
3.2.2. Soman-induced SE
Rats treated with midazolam (3mg/kg) 40min after SE had greater
24 h survival (90%) compared to rats treated with saline or with 1mg/
kg midazolam (50% and 60% respectively). The values of EEG power
integral of treatment groups were compared in specific time periods
(during pre-treatment SE, and during the first hour or the first 6 h after
treatment). EEG power integral (a measure of EEG seizure severity)
increased in all GD-exposed rats during SE compared to rats that were
not exposed to GD, and there were no differences between groups.
During the first hour after treatment, rats that received midazolam had
a significant reduction of EEG power compared to those that received
only vehicle, but by 6 h after exposure there was no difference between
these groups (data not shown). Rats treated with ketamine 30mg/kg
were similar to midazolam-treated animals. Rats treated with 30mg/kg
ketamine +3mg/kg midazolam after 40min of GD-induced SE had
reduced EEG power integral (reduced seizure severity) during the 1 h
after treatment. In addition, during the 1 h and the first 6 h time periods
after treatment, rats treated with ketamine - midazolam combination
had a greater decrease in percent EEG power integral (70%) compared
to midazolam monotherapy (14%) (p < 0.01 at 1 h, p < 0.05 at 6 h).
The first hour is the critical time to reduce neuronal injury (which
appears within 20min. of SE onset) and pharmacoresistance, which
increases with seizure burden (Niquet et al., 2016a,b). Higher doses of
ketamine (not shown) did not provide additional therapeutic benefits
but increased mortality.
3.2.3. Effect of GABAAR agonist-NMDAR antagonist combinations on long-
term consequences of cholinergic SE
3.2.3.1. Neuronal injury. No neuronal injury was detected in any
ketamine-treated animals in CA3 (Fig. 3a) or CA1, suggesting an
NMDAR-dependent mechanism of injury in hippocampal pyramids.
Rats treated with the midazolam – ketamine – valproate combination,
which stopped RSE rapidly, showed remarkable reduction of neuronal
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injury, but rats treated with triple-dose ketamine alone, which was
poorly effective in stopping EEG seizures and did not terminate RSE,
showed equally good protection. Thus this appeared to be related to the
neuroprotective properties of ketamine, rather than to the ability of
NMDAR antagonist-containing combinations to stop RSE. This has
therapeutic implications: it suggests that the early use of ketamine for
neuroprotection, regardless of or in addition to its ability to stop
seizures, might be a useful strategy in RSE and SRSE. It would be
interesting to retrospectively look at MRI evidence of brain damage and
brain atrophy in the clinical use of ketamine for RSE, although it is
often used so late in the course of RSE that most vulnerable neurons
might have been lost before treatment was initiated.
This neuroprotection is all the more remarkable because treatment
was administered after 40min of EEG seizures, and signs of neuronal
injury have been documented to occur within 20min of seizure onset in
a model of lithium – pilocarpine SE milder than the model we used
(Fujikawa, 1996). It is likely that ketamine treatment reversed neuronal
injury in hippocampal principal neurons, in spite of its delayed de-
livery. The fact that ketamine neuroprotection was less complete in
dentate hilus than in CA1 or CA3 was expected, and suggests that
neuronal injury in that area is less dependent on NMDAR activation
than in CA1. It confirms that the mechanisms of neuronal injury from
the same seizures can vary with the brain region (Lopez-Meraz et al.,
2010).
3.2.3.2. Spontaneous recurrent seizures. Fig. 3b shows that treatment
with the midazolam+ketamine combination prevented
epileptogenesis. No rat treated with that combination displayed any
SRS (dual therapy: 0 SRS, n=10, p < 0.0001 vs valproate controls).
In the Tetz model, no untreated SE control survived long enough to be
tested (6–8weeks), so that we used as SE controls a group treated with
valproate, which reduced mortality without changing the seizures in a
measurable way. All rats which received 270mg/kg of valproate, which
increased long-term survival but did not alter the severity of SE,
developed SRS (4.6 ± 1 SRS per week, n=7). Some rats treated
with double-dose ketamine developed SRS (p < 0.05 vs dual therapy)
and so did some rats from the double-dose midazolam group, but
differences with dual therapy were not significant. We do not know to
what extent these results reflect a reduction in SE severity and duration
versus a true antiepileptogenic action.
After soman-induced SE, 83.3% of untreated rats (VEH) that sur-
vived beyond 1week (n=5 of 6 survivors) developed SRS, versus 80%
in the midazolam-treated group (n=8 of 10 survivors) and 75% in the
ketamine-treated group (n=3 of 4 survivors). Treatment with the
midazolam - ketamine combination (n=2 of 8) had a 25% incidence of
SRS (Fig. 3c). The percent of animals that developed SRS in the keta-
mine-midazolam group was significantly lower than the midazolam
only group (p < 0.05).
3.2.3.3. Spatial memory deficit. In the Tetz model, SE-associated loss of
spatial memory in the Morris Water maze (Morris, 1984) (Fig. 3d) was
impaired in the valproate group (n= 7) compared to sham (no SE)
controls (n=8). Again, no untreated SE control survived long enough
to be tested (6–8 weeks). In the acquisition test, the midazolam +
ketamine group (n=10) was undistinguishable from sham (no SE)
controls and performed better than the valproate group (n=7,
p < 0.0001), the midazolam group (n=10; p < 0.05) and the
ketamine group (n=10; p < 0.01). In the retention test, the
valproate group was significantly different from the dual therapy and
sham groups (which did not differ from each other) by Kruskal-Wallis.
In soman-induced SE (Fig. 3e), spatial memory deficits were evident
in the groups treated with midazolam (GD/MDZ) or ketamine (KET/
MDZ) monotherapy, while rats treated with a combination of mid-
azolam and ketamine (GD/MDZ/KET) were not statistically different
from untreated, no-SE controls (NO GD).
Altogether, these observations show that combining a GABAAR
agonist and an NMDAR antagonist reduces not only the severity of SE
but that of its long-term consequences as well.
Fig. 2. A) Response of high-dose lithium-pilocarpine RSE to monotherapy with the GABAAR agonist diazepam or the NMDAR antagonists dizocilpine or ketamine,
and to combination therapy with GABAAR agonists coupled with NMDAR antagonists. Cholinergic RSE is terminated by GABAAR agonist – NMDAR antagonist
combinations, and fails to stop with monotherapy, even at high dose (diazepam 20mg/kg, not shown). Dz5: diazepam 5mg/kg; MK1: dizocilpine 1mg/kg; Ket 10:
ketamine 10mg/kg; Dz5+MK1: diazepam 5mg/kg combined with dizocilpine 1mg/kg; Dz5+Ket 10: diazepam 5mg/kg combined with ketamine 10mg/kg. *, **,
***: p < 0.05. 0.01 or 0.001 compared to Diazepam 5mg/kg. #, ##: p < 0.05 or 0.01 compared to dizocilpine 1mg/kg. $,$$,$$$: p,0.05, 0.01 or 0.001 compared
to ketamine 10mg/kg. Values are median ± interquartile range. Kruskall-Wallis with Dunn's multiple comparisons. B) shows the results of treating sc soman-
induced SE with benzodiazepine monotherapy, with ketamine monotherapy, or with a GABAAR agonist-NMDAR antagonist combination, 40min after seizure onset.
EEG power before treatment (SE) was similar in all experimental groups. Treatment with midazolam 3mg/kg (GD/MDZ/SAL) or with ketamine 30mg/kg reduced
EEG power slightly compared to untreated animals. The midazolam 3mg/kg / ketamine 30mg/kg combination (MDZ/KET) reduced the EEG power integral much
better than midazolam or ketamine monotherapy. ***p < 0.001; **p < 0.01; p < 0.05. Data shown are mean ± S.E.M. These results suggest that the midazolam-
ketamine combination is efficacious in reducing EEG seizure severity against soman-induced SE.
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3.2.4. Drug selections based on the receptor trafficking hypothesis are more
effective than guideline-recommended combinations of AEDs
3.2.4.1. Efficacy in stopping RSE. We wanted to examine whether a drug
combination based on the receptor trafficking hypothesis, offered any
advantage over drug combinations suggested by current evidence-based
clinical guidelines, which recommend initial benzodiazepine
monotherapy followed by an AED (e.g. fosphenytoin), then by
another AED (e.g. valproate) or anesthesia (Glauser et al., 2016). We
compared the effect of the midazolam 3mg/kg-fosphenytoin 50mg/kg-
valproate 90mg/kg combination (which follows AES guidelines) with
the combination midazolam 3mg/kg-ketamine 30mg/kg-valproate
90mg/kg, which targets seizure-induced changes in GABAA and
glutamate receptors. Drugs were delivered simultaneously in both
groups, 40min after EEG seizure onset. The latter combination was
far more effective in reducing the number of post-treatment seizures
(Fig. 4A), the EEG power integral over the first hour post-treatment
(Fig. 4B), the time needed for EEG amplitude to decline to twice the
pre-seizure baseline (Fig. 4C) and the number of post-treatment spikes
for 24 h (Fig. 4D).
3.2.4.2. Clinical relevance. The relevance of these results in rodents to
the treatment of SE in humans is unknown. While receptor properties
are similar in both species, and benzodiazepine pharmacoresistance has
been observed clinically (Silbergleit et al., 2012; Treiman et al., 1998),
circuitry and brain size are quite different in rats and humans, and the
heterogeneity of clinical SE may limit the applicability of conclusions
drawn from any animal model to clinical situations. However, the
oncology experience has shown that drug dosage can be compared
across species by using body surface area rather than body weight as a
denominator (Pinkel, 1958; Guidance for Industry, 2005; Reagan-Shaw
et al., 2008; Kaestner and Sewell, 2007). Comparing our 250–300 g rats
to 70 kg humans by that method suggests that the doses of valproate,
fosphenytoin and levetiracetam used in this study are not above the
“human equivalent dose” (HED) derived from the clinical literature
(Chen and Wasterlain, 2006; Gezalian et al., 2014; Glauser et al., 2016),
while the midazolam dose used is slightly higher than the HED and the
ketamine dose is three times the recommended HED (Chen and
Wasterlain, 2006) but is lower than the dose used in patients with
refractory SE who responded to ketamine (Gaspard et al., 2013).
However, we have to remember that this method does not take into
Fig. 3. a) Untreated SE controls showed extensive neuronal injury in CA3, 48 h after SE. Animals treated with midazolam or valproate monotherapy showed no
significant reduction of neuronal injury. Polytherapy with combinations of midazolam/ketamine or midazolam/ketamine/valproate at 40min after seizure onset
showed nearly complete protection from neuronal injury, but so did ketamine monotherapy. Results in CA1 were similar to CA3. In the dentate hilus, neuroprotection
was less complete. Neuronal injury measured by unbiased stereology showed only an approximately 50% reduction in Fluoro-Jade-positive cells in all three keta-
mine-treated groups. *p < 0.05; **p < 0.01 by Kruskal-Wallis analysis followed by Dunn's test. b) Midazolam–ketamine dual therapy prevents epileptogenesis.
Graph showing the number of SRS per week, ≥6weeks after high-dose lithium-pilocarpine SE. The group treated with midazolam–ketamine dual therapy had no
SRS. We used valproate monotherapy as our control group because of high mortality in the untreated control group. *p < 0.05, **p < 0.01 and ****p < 0.0001
versus valproate (Kruskal-Wallis followed by Dunn's test). From Niquet et al., 2016a, b. c) SRS after soman-induced SE. Treatment with the midazolam-ketamine
combination reduced the incidence of SRS during the first 2 weeks after SE, compared to midazolam monotherapy (p < 0.05). d) Treatment of lithium-pilocarpine
SE with the midazolam–ketamine combination reduces behavioral deficits. (Top) Performance in the Morris water maze shows the latency to reach the hidden
platform (y-axis) on each testing day (x-axis). Acquisition is slower in the group treated with triple-dose midazolam monotherapy than in “no SE” controls. The group
treated with midazolam+ketamine+ valproate is indistinguishable from “no SE” controls. (Bottom) Latency to reach the hidden platform during the retention test
also shows a significant reduction of latency in the combination therapy group compared to the triple-dose monotherapy group. **p < 0.01 versus valproate
270mg/kg (by Kruskal-Wallis followed by Dunn's test). Data are presented as mean ± standard error of the mean (SEM). *p < 0.05 versus Mz4.5+Ket45;
**p < 0.01 versus Mz4.5+Ket45 and ****p < 0.0001 versus Mz4.5+Ket45 by two-way ANOVA. e) After sc Soman SE, spatial memory acquisition in the Morris
Water Maze is slower in rats treated with midazolam (9mg/kg) or ketamine (90mg/kg) monotherapy than in controls which were not exposed to soman (“no GD”)
and had no seizures (*p < 0.05). In contrast, the combination of midazolam (3mg/kg) and ketamine (30mg/kg) was not significantly different from controls.
Fig. 4. The midazolam-ketamine-valproate combination, which targets seizure-induced changes in GABAA and glutamate receptors, is more effective that the
midazolam-fosphenytoin- valproate combination, which follows American Epilepsy Society guidelines (Glauser et al., 2016). The graphs show the number of
computer-detected seizures per 24 h (A), the ratio of EEG power integral over the first hour to initial EEG power at baseline (B), the time needed for EEG amplitude to
decline from its very high value during SE to twice the pre-seizure baseline (C) and the number of computer-detected spikes per 24 h (D). The combination of 3 mg/kg
midazolam, 30mg/kg ketamine and 90mg/kg valproate (n= 10) was more potent than the combination of 3mg/kg midazolam, 50mg/kg fosphenytoin and 90mg/
kg valproate. *p < 0.05, or***p < 0.001 by Mann-Whitney analysis. Fosphenytoin is expressed in Phenytoin Equivalents.
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account differences in pharmacokinetics, and can provide a rough dose
approximation at best.
3.2.5. Drug combinations based on the receptor trafficking hypothesis are
synergistic and have a high efficacy/toxicity ratio
Isobolograms (Tallarida, 2000, 2006) suggest that the midazolam-
ketamine-valproate combination potentiates the therapeutic response
without potentiating drug toxicity (Fig. 5), so that the therapeutic index
(Muller and Milton, 2012) is improved by switching from mono- to
polytherapy. The key to therapeutic success is the ratio of efficacy to
toxicity. If a combination of drugs potentiates both efficacy and toxi-
city, the latter will reduce the amount of drug tolerated, and nothing is
gained. Fig. 5 shows that toxicity was simply additive between the three
drugs of the combination, and that the therapeutic response was sy-
nergistic. As a result of that synergy, this three-drug combination de-
livered a greater therapeutic response than monotherapy for the same
level of drug-induced toxicity. The mechanism of that synergy is un-
known, since the drugs involved have no known direct interactions at
the molecular level, and the effect is too rapid to be due to pharma-
cokinetic interactions. This synergism was powerful enough to over-
come pharmacoresistance at the times tested in this study: the dia-
zepam+ketamine+ valproate combination stopped seizures at a time
when pharmacoresistance to high doses of diazepam (20mg/kg) was
clearly present.
3.2.6. Timing of drug delivery is key
Standard practice in treating SE is sequential polytherapy, in which
we wait for the first drug to fail before giving the second drug, and for
the second drug to fail before giving the third drug (Glauser et al.,
2016). This has the advantage of minimizing the number of drugs de-
livered to responders, but the disadvantage of delaying delivery of the
second drug by at least 30min., and delivery of the third drug by at
least 1 h. The RAMPARTS study (Silbergleit et al., 2012) suggests that
even small delays in treatment can result in differences in outcome. In
order to mimic clinical situations where drugs are only injected after
the previous treatment fails, we treated SE with the same drugs at the
same dose in two groups of rats. In one group the three drugs were
injected simultaneously. In the second group the second drug was in-
jected 30min after the first, and the third drug was delivered 30min
after the second drug (Fig. 6A). Simultaneous polytherapy was far more
effective than sequential monotherapies in reducing the post-treatment
EEG power integral during the first hour (Fig. 6B), or the first 6 h after
treatment; in reducing the time needed for EEG amplitude to decline to
twice the pre-seizure baseline (Fig. 6C) and in reducing the number of
post-treatment seizures (not shown). By those measures, sequential
monotherapies were not significantly different from high-dose benzo-
diazepine monotherapy, matching the clinical experience where the
second and third drug used in sequential polytherapy have a low suc-
cess rate (Treiman et al., 1998).
The far greater efficacy of simultaneous polytherapy over sequential
monotherapies at the same dose is compatible with increasing phar-
macoresistance, associated with seizure-induced increases in receptor
trafficking, during the delay between sequential drug injections. The
RAMPART trial (Silbergleit et al., 2012) showed that earlier treatment
leads to better results, and that a brief gain of time (4min.) can make a
significant difference in outcome. Fig. 6 confirms that principle in the
treatment of cholinergic RSE.
4. Conclusions
Traditional treatments of cholinergic seizures have been empirical,
and fail to overcome pharmacoresistance when treatment is delayed.
Our improving knowledge of the mechanisms of seizure-induced
pharmacoresistance should prompt us to base treatment on pathophy-
siology. Cholinergic SE involves key changes in GABA and glutamate
receptors, yet we continue to treat it with a single GABAergic drug,
leaving changes in excitatory networks untreated. We also continue to
delay administration of the second drug until the first one has failed,
and administration of the third drug until the second one has failed,
ignoring evidence that pharmacoresistance increases with time and
with seizure burden. Replacing a benzodiazepine (diazepam) with an-
other benzodiazepine with better pharmacokinetics (midazolam) is
bound to fail because it does not address the main reason for benzo-
diazepine pharmacoresistance, which is the loss of synaptic GABAAR.
Clinical trials comparing monotherapies are bound to show only minor
differences between drugs, since each one treats only part of the pro-
blem, unless one practices “polytherapy” with a single drug which has
multiple mechanisms of action (Krishnan et al., 2017).
We have tested the hypothesis that decreases in synaptic GABAAR
and increases in synaptic glutamate receptors are key elements of the
Fig. 5. Contribution of drug interactions to toxicity and efficacy. (A) Drug interactions do not contribute to the toxicity of the diazepam-ketamine-valproate
combination. The measured toxicity of the drug combination (red dot) is exactly in the plane connecting individual drugs dosages producing a similar toxicity score
(TD50's). Therefore, for the diazepam-ketamine-valproate combination, drug toxicity is neither synergistic nor antagonistic; it is simply additive. (B) Drug inter-
actions contribute to the efficacy of the diazepam-ketamine-valproate combination. The efficacy of the three-drug combination in reducing the time needed for EEG
power to fall to two times the pre-seizure baseline power, a good measure of seizure termination (red dot) is far below the plane connecting individual drug dosages
producing a similar efficacy score (ED50's). Therefore, for the diazepam-ketamine-valproate combination, drug effects show strong positive cooperativity and are
synergistic. This also means that the efficacy/toxicity ration of this combination is higher than the sum of its individual components, and its therapeutic index is
improved by the use of this specific combination. From Niquet et al. (2017a, b). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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initiation and maintenance of cholinergic SE, and that both need to be
treated to overcome seizure-induced pharmacoresistance when treat-
ment is delayed. Our results support that hypothesis. In the treatment of
severe benzodiazepine-refractory cholinergic SE, drug combinations
which include a GABAAR agonist and a NMDAR antagonist are far more
effective at stopping seizures than higher-dose monotherapy, or than
other drug combinations, supporting a key role of GABAA and gluta-
mate receptor trafficking in the pathophysiology of cholinergic SE. This
is true in soman-induced SE as well as in a high-dose model of lithium-
pilocarpine SE. These drug combinations not only terminate cholinergic
RSE, but reduce or abolish its long-term consequences: neuronal injury,
spatial memory deficits and epileptogenesis. Unlike benzodiazepines,
they work when treatment is delayed by 40min. Their seizure-stopping
effects show positive cooperativity between drugs, so that their ther-
apeutic index is improved by their synergistic interaction.
We compared this treatment to others inspired by standard clinical
practice. Late treatment with the midazolam-ketamine-valproate com-
bination was more potent than the midazolam-fosphenytoin-valproate
combinations, showing that not all triple therapies show synergism, and
suggesting that simultaneously targeting GABAAR and glutamate re-
ceptor changes is a valid therapeutic strategy. The simultaneous
administration of the three drugs was far more efficient in stopping
seizures than the standard practice of injecting the drugs sequentially,
suggesting that timing of treatment is essential, and that an early
polytherapy arm should be included in future clinical trials.
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Fig. 6. Importance of the timing of drug delivery. A) Experimental flow: In the simultaneous group, the combination of midazolam 3mg/kg, ketamine 30mg/kg and
valproate 90mg/kg was administered simultaneously 40min after SE onset. In the sequential group, the same drugs at the same dose were injected 30min apart.
B–C) The graphs show the ratio of EEG power integral to initial EEG power at baseline over the first hour (B), and the time needed for EEG amplitude to decline to
twice the pre-seizure baseline without EEG bursts (C), indicating seizure termination. Simultaneous polytherapy (n=10) was far more effective than sequential
monotherapies (n=8–9) or higher-dose midazolam (n= 10) in reducing EEG power, and in stopping SE. * p < 0.05, * p < 0.05, ** p < 0.01, **** p < 0.0001
by ANOVA followed by Tukey's multiple comparison or by Kruskal-Wallis analysis followed by Dunn's test.
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